Search Results

Discovery at Discovery on Target 2025 — The Track You Can’t Miss If you work in drug discovery  or biotech Over the years, we’ve built a global network of researchers, biotech leaders, and pharma innovators who together. 🚨 Mark your calendar for the GPCR Happy Hour Join us at GPCR Happy Hour , where scientists, biotech

Tools The Story Behind Celtarys – From Chemistry to Company   How does a medicinal chemist become a biotech Explore this week’s research, tools, and biotech insights in one place.

GPCR Foundry  — our R&D and biotech hub designed to bridge GPCR science with execution. The Dr. GPCR Foundry: Science Meets Execution The Foundry is where we bring together biotech innovators, Venture , he shares decades of expertise in an accessible, on-demand format for scientists across academia, biotech Anyone who joins Premium before these changes go live will be grandfathered at their current rate , as

Kenakin Trusted insights across biotech, pharma, and academia 💎 $2,999/year — one conference cost = embracing serendipity, Eric shares the mindset (and messy origin stories) that shaped tools now used across biotech GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need

Dive into this week’s research, tools, and biotech updates all in one place.

Highlights: • The Foundry Arrives : R&D meets biotech with real-world acceleration, strategic consulting GPCR scientists, translational pharmacologists, biotech drug discovery teams, and decision-makers who

In a field like GPCR research (where data complexity and failure rates are high), scientific rigor thrives work at Alkermes didn’t just improve drug screening outcomes, it redefined what great leadership in biotech

GPCR Premium Membership Gives You an Edge Premium gives GPCR scientists and biotech teams a single, trusted Researchers, pharmacologists, biotech teams, and decision-makers who rely on accurate, efficient, interpretation-first Help us reach more scientists by providing quick rating on Spotify or Apple Podcasts — and a YouTube

Explore this week’s research, tools, and biotech insights in one place.

Biotech teams, CRO alliances, and academic consortia face the same challenge: how to align incentives This ecosystem design blueprint applies to biotech teams and academic consortia alike.

Designing for penetration —balance on/off rates to reach inner tissue, not just peripheries. Kenakin Trusted insights from biotech, pharma, and academia 🎬 Plus New: Lesson Trailers   Curious about GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need

His hybrid path is a model of possibility for professionals in the biotech industry who still dream of

GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need tools, translational strategy, classified updates, and curated jobs—trusted by scientists, teams, and biotech

🔹 Spot the opportunity → Why Catalio is betting big when others pull back Amid biotech slowdowns

need now: a pragmatic framework to interpret kinetic binding experiments and recognize when a drug’s rate Terry Kenakin’s featured talk on “The Kinetics of Allostery” offers a rare live glimpse into advanced insights from major conferences, emerging research, and expert commentary Whether you’re a pharmacologist, biotech GPCR scientists, translational pharmacologists, biotech drug discovery teams, and decision-makers who

Explore this week’s research, tools, and biotech insights in one place.

Did you know that each month we collect the most recent #GPCR publications and the newest Biotech/Pharma

(“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today Vraniak served as Chief Financial Officer of Evaxion Biotech A/S, an AI enabled immuno-oncology company

School of Medicine to Receive $3-Million Award from ARPA-H’s Sprint for Women’s Health Nxera Pharma Wins Biotech Year and Financing Deal of the Year at the Citeline Japan Awards 2024 GPCR therapies: Eight promising biotechs

productive lab—it accelerated outcomes and laid the cultural foundation for the next generation of biotech insights from major conferences, emerging research, and expert commentary Whether you’re a pharmacologist, biotech

Industry News Domain Therapeutics was one of the 4 Biotech Trophy nominees at 2023 HealthTech awards. The delisting dilemma: Why do so many biotechs face being kicked off the Nasdaq?. (April 20 - 21, 2023) Swiss Biotech Day (April 24 - 25, 2023) SLAS Europe 2023 Conference and Exhibition

Explore this week’s research, tools, and biotech insights in one place.

I've seen this pattern unfold across biotech, academia, and nonprofits. Traditional roles rarely gave me the freedom to implement these changes at the scale needed.

Explore this week’s research, tools, and biotech insights in one place. The insights are ready.

with your topic suggestions 🆕 Weekly new releases to stay ahead of the science 🧠 Content built for biotech Rare-earth europium complexes offered potential—but the chemistry was brutal. Because they give researchers something rare in CNS work: clarity in complexity. GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need

The Boston biotech revealed Wednesday afternoon that it would downsize its research to focus on its lead

Industry News Biotech startup Structure pulls off rare IPO, raising $161M 3-drug combo leads to 'unprecedented Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) arcoscreen is one of the 13 biotech

About Celtarys Research Celtarys Research is a biotech company based in Spain that specializes in the

pathway of opioid drugs into cellular structures Inversago Pharma will present at BBHIC 2023 Orion Biotechnology attended the Swiss Biotech Day Addex Therapeutics attended the Swiss Biotech Day Sosei Heptares presented

January 2022 "G-protein-coupled receptors’ star has been on the rise in biotech in recent years as researchers